Skip to main content

Sensex conquers Mt 63K | Ridham Desai on road ahead for D-St | 8 multibaggers held by 20 MFs

To keep you updated, we send ET Markets Newsletter to your mailbox. In case, you wish to Unsubscribe Click Here

DAILY BRIEF
Subscribe to ET Prime

Wed, Nov 30, 2022
#Q4Results#Coronavirus#StimulusPackage#ExpertViews#StockRecos
TOP OF THE DAY
Sensex scales Mt 63K for the first time
The 30-share Sensex ended 418 points higher to scale Mt 63K, while its broader peer, Nifty50, ended above the ...
MF Darlings! These 8 multibaggers of 2022 are held by at least 20 funds
Money-making Ideas: Wipro among 8 stocks set to rally in the short term
As Nifty rebounds from 1-yr lows, heavyweight RIL has little to contribute
January effect in offing on D-St? Here's what the history suggests
India a expensive market & it's time to diversify, look at Nasdaq: Kamath
Celebrating the success of Indian MSMEs
Auto sales preview: PV demand remains strong, muted show for 2Ws
For Fastest News Updates, Incisive Stock Analysis by ET Experts and more.Download ETMarkets App!

Top Gainers

NSE
4 companies (largecap) appreciated more than 5%
Varun Beverages 9.04%
Go Fashion 8.42%
More from Gainers

Top Losers

NSE
4 companies (largecap) price decreased more than -3%
New India Assurance -5.00%
Vivo Collaboration Solutions Ltd. -4.95%
More from Losers

52 Week High

NSE
64 companies touched new 52-week high today
HLV Ltd. 20.00%
Likhitha Infra 15.57%
More from 52 Week High
Ridham Desai on factors that'll drive bulls in 2023
"In 2023, as we head into the second half, the market will start making a call on the elections and start pric...
Why Nifty is outperforming as other markets muddle through
5 reasons which make SBI an attractive buy now; re-rating possible
Uniparts India IPO kicks off: Should you subscribe?

Experience your trusted ET newspaper. Now in a brand new way.
The Economic Times print edition. Experience it now with your ET Prime membership.

Read Today's Print Edition
icon
Market moguls
icon
Podcast
icon
Video
REITs trump physical real estate on most counts; here's why
Market Watch: Nifty may test 19,000 soon
Sensex drops over 300 pts on global selloff, Nifty below 11,200
RECOMMENDATIONS
Devyani International Ltd.
Buy Devyani International, target price Rs 220: HDFC Securities
Buy
Godrej Properties Ltd.
Buy Godrej Properties, target price Rs 1500: Prabhudas Lilladher
Buy
Glenmark Pharmaceuticals Ltd.
Buy Glenmark Pharmaceuticals, target price Rs 580: Nomura, India
Buy
Laurus Labs Ltd.
Sell Laurus Labs, target price Rs 350: Kotak Institutional Equities
Sell
Bharti Airtel Ltd.
Buy Bharti Airtel, target price Rs 930: JM Financial
Buy
Live Stream
Trade & Investing Ideas by Experts. Community Chat.
1
Actionable Insights

Get Insights from experts and make your dreams come true

 2
Markets Movement

Watch live & recorded sessions to understand what is moving the market

 3
Make Smart Decisions

Chat live with the experts to get your questions answered
Watch Now
What recession blues? D-St can rise another 9%
The Reserve Bank of India has raised its key policy rate a relatively modest 190 basis points since May to 5.9...
Tech View: Nifty forms long bullish candle on daily charts
SBI, Airtel among 10 stocks that got most number of upgrades
Investors want more of India, says Goldman Sachs' Sengupta
Quick Links
Markets Live | Market Stats | IPOs | Technicals | Commodities | Forex
Get In-depth analysis of stocks worth Rs 1499 complimentary with your ETPrime membership!
Know More
Follow Us:
Download ET Markets App:
About us|Advertise with us|Feedback|Sitemap|Code of Ethics
More Newsletters: Daily Newsletter | Markets Morning | ET Investment Opportunities | Wealth | View all

© 2022 Times Internet Limited.

To ensure delivery directly to your inbox, please add newsletter@economictimesnews.com to your address book today. If you are having trouble viewing this newsletter, please click here, To unsubscribe or edit your subscriptions please click here

Comments

Post a Comment

Popular posts from this blog

The first drug for a common, deadly liver disease is here – and more are coming

VIEW IN BROWSER | SUBSCRIBE TUE, MAR 19, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good morning!  Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for the condition.    In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals ' drug " Rezdiffra ," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates.    So, why is this approval so important?    First of all, people suffering from the disease badly need a treatment. Rezdiffra is specifically approved to treat patients with nonalcoholic steatoh
Post a Comment
Read More

J&J, Merck and Bristol Myers Squibb are in the hot seat

VIEW IN BROWSER | SUBSCRIBE TUE, JAN 30, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com .    Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead.    CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday.   It took subpoena threats from the senator, but J&J CEO Joaquin Duato and Merck CEO Robert Davis have agreed to testify after both executives declined earlier requests to appear at the Senate HELP committee's hearing. They join Bristol Myers Squibb CEO Chris Boerner, who agr
Post a Comment
Read More

How competitive can Roche be in the weight loss drug market?

VIEW IN BROWSER | SUBSCRIBE TUE, SEP 17, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon!  Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating. But can the Swiss company develop drugs that can compete with that duopoly?  The answer isn't clear yet.  We need to see more data from longer and larger clinical trials, which will likely take years for Roche to conduct.  But the company last week presented more early-stage data more early-stage data on its experimental obesity injection and pill, which some analysts said raised concerns about how competitive those products can be if they enter the space. Some analysts said the new results showed that both drugs – which Roche acquired through its nearly $3 billion acquisition of Carmot Therapeutics in December – caused a higher rate of side
Post a Comment
Read More